

3 November 2023

---

*Not for release to US wire services or distribution in the United States*

Dear Optionholder,

#### NOTIFICATION TO OPTIONHOLDERS

We are writing to you in relation to your option holding in Anatara Lifesciences Limited (ASX: ANR) ("**Anatara**" or the "**Company**").

On Friday, 3 November 2023, Anatara announced the launch of a A\$1.055 million entitlement offer of new fully paid ordinary shares (**New Shares**) at an offer price of A\$0.022 per New Share (**Entitlement Offer**). The Entitlement Offer is comprised of a 2 - for- 5 pro rata non-renounceable entitlement offer of New Shares to raise gross proceeds of approximately A\$1.055 million.

The Entitlement Offer is being made without a prospectus or disclosure document in accordance with section 708AA of the *Corporations Act 2001* (Cth).

The New Shares will rank equally in all respects with Anatara's existing shares. If an eligible shareholder's entitlement results in a fraction of a New Share, the shareholder's entitlement will be rounded up to the nearest whole number.

An offer booklet for the Entitlement Offer will be lodged with the ASX and made available on Monday, 13 November 2023 to eligible retail shareholders with a registered address in Australia or New Zealand as at 7.00pm (Melbourne time) on Wednesday, 8 November 2023 (**Record Date**).

#### Optionholders

The Company is giving you notice that as an optionholder of the Company, if you wish to participate in the Entitlement Offer with respect to your options (**Options**), you must exercise your Options before the Record Date. If you require an option exercise form, please call the Share Registry, Computershare on 1300 850 505 (within Australia) and +61 3 9415 4000 (outside Australia).

There is no obligation for you to exercise your Options. This letter is intended to inform you of your rights in relation to your Options and the Entitlement Offer. If you do not wish to participate in the Entitlement Offer you do not need to take any action.

#### Questions

If you have any questions in relation to the above, please contact the Share Registry, Computershare, on 1300 850 505 (within Australia) and +61 3 9415 4000 (outside Australia) at any time between 8:30a.m and 5:00p.m. (Melbourne time) on Monday to Friday during the Entitlement Offer period.

On behalf of the Board, I invite you to consider this investment opportunity and thank you for your continued support.

Yours sincerely  
David Brookes  
Executive Chair  
Anatara Lifesciences Limited

## **Disclaimer**

### **Forward looking statements**

This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Anatara, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Anatara's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Anatara, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this document. The forward-looking statements are based on information available to Anatara as at the date of this document. Except as required by law or regulation (including the ASX Listing Rules), none of Anatara, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

### **Not an offer in the United States**

This document has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction in which such an offer would be illegal. Any securities described in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or jurisdiction of the United States. Accordingly, the securities described in this document may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other jurisdiction of the United States.